Overview

A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer

Status:
Completed

Trial end date:
2021-04-28

Target enrollment:

Participant gender:

Summary

The purpose of this study is to test the safety and effectiveness of two investigational drugs (drugs that are not currently approved by the FDA) given in combination with radiation therapy or ablation.

Phase:

Phase 2

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Collaborators:

AstraZeneca
MedImmune LLC

Treatments:

Antibodies, Monoclonal
Durvalumab
Tremelimumab